Date, Time & Location: Monday, June 26 | 13:15PM - 14:30PM | Riverbank 3
Panelists: Jamie Erskine, Richard Charter, Ben Forrest, Guy Maddern
Summary: Building on the results of a recent research study into HTA best practices for Robotic-Assisted Surgery, this panel session will open conversation on the challenges in assessing a rapidly developing technology. We will explore how HTAs can guide decision-making and policy discussions and consider the future of robotic surgery and related digital technologies. How can HTAs be ready?
Date, Time & Location: Monday, June 26 | 13:15PM - 14:30PM | E 3
Panelists: Haitham Tuffaha, Dalia Dawoud, Julia Lewis, Ann Single, Colman Taylor
Summary: Coverage with Evidence Development (CED) could provide a flexible funding pathway to list promising technologies conditional on collecting evidence. The uptake of CED by Health Technology Assessment agencies, however, is limited. The panel aims to discuss the barriers and facilitators for CED implementation from different perspectives and how to align stakeholders’ perspectives to facilitate the implementation of CED in practice.
Date, Time & Location: Monday, June 26 | 13:15PM - 14:30PM | Riverbank 6
Panelists: Maoling Wei, Jian Ping Liu, Myeong Soo Lee, Jennifer Hunter, Americo Cicchetti
Summary: Considering the growing interests for HTA and lots of publications on traditional, complementary & integrative healthcare (TCIH), it is necessary to provide a platform to discuss the core issues and explore the role of HTA in TCIH.
Date, Time & Location: Monday, June 26 | 13:15PM - 14:30PM | Riverbank 5
Panelists: Murilo Contó, Rossella Di Bidino, Paul Dale, Aline Silveira Silva, Michael Simmons
Summary: Due to the intrinsic particularities and the great variability of the technological design, HTA applied to medical devices has been a challenge around the world. This panel aims to disseminate the main advances in terms of methods, main differences between drugs and devices and the need for different HTA approaches to assessment medical devices.
Date, Time & Location: Monday, June 26 | 13:15PM - 14:30PM | Hall C
Panelists: Valentina Strammiello, Sally Wortley, Haley Andersen, Mark Brooke, Eric Low, Jenniffer Prescott
Summary: The Scottish Medicines Consortium (SMC) Summary of Information for Patient Groups (SIP) template was adapted for international use. This session covers the outcomes from the pilots in Australia and England followed by a discussion involving HTA, industry and patient representatives on the lessons learned and its potential as an information resource to support harmonised practice throughout the health technology lifecycle
Date, Time & Location: Monday, June 26 | 13:15PM - 14:30PM | Riverbank 7
Panelists: Alicia Granados, Neil Bertelsen, Alfonso Iorio, Elena Nicod
Summary: Patient Reported Outcome Measures (PROMs) are used to capture how patients’ quality of lives (QoL) are impacted from disease and treatment. PROMs are particularly important in rare disorders where clinical outcomes may be unclear, but are challenging to develop, administer and interpret. This panel will discuss how to best capture and interpret QoL evidence when evaluating a rare disease therapy.
Date, Time & Location: Monday, June 26 | 13:15PM - 14:30PM | Riverbank 4
Panelists: Dan Ollendorf, Rebecca Trowman, Tracy Merlin, Kyle Hvidsten, Stella O'Brien, David Hailey
Summary: This interactive panel session will report back and build upon the discussions from the 2023 Global Policy Forum (GPF). An introductory presentation will summarize the discussions and major outcomes of the GPF meeting and will be followed by reactions from key stakeholders including HTA bodies, patients and industry representatives. Interaction with the audience will be enhanced by live polling.
Date, Time & Location: Monday, June 26 | 13:15PM - 14:30PM | Riverbank 8
Panelists: Janet Bouttell, Andrew Partington, Carla Fernandez, Alicia Norman, Jonathan Karnon
Summary: Is early HTA just HTA done earlier? This panel discusses the why, when, what and who of early HTA and explores how each facilitate timely patient access to valuable innovation.
Date, Time & Location: Monday, June 26 | 13:15PM - 14:30PM | E 1
Panelists: Alric Rüther, Wim Goettsch, Laura Sampietro Colom, Keng Ho Pwee, Steve Pearson
Summary: The philosophical approach to “Quality” given by R. Pirsigs famous “Zen and the art of motorcycle” is taken as background for the discussion about the interference of cultural implications in HTA processes and products. It is expected to get a better view beyond the mainly discussed understanding of the evidence-based approach.
PANEL SESSION 2
17:25 - 18:40
Date, Time & Location: Monday, June 26 | 17:25PM - 18:40PM | Gilbert Suite
Panelists: Evi Germeni, Barry Liden, Simon Fifer, Deborah Marshall
Summary: Incorporating patient preference information (PPI) into HTA decision making is increasingly being viewed as a priority. Efforts, however, to incorporate such data in benefit/risk assessments remain scarce and fragmented. This panel will discuss the role of speed and rigour in ensuring that PPI is better integrated into HTA submissions.
Date, Time & Location: Monday, June 26 | 17:25PM - 18:40PM | Riverbank 5
Panelists: Laura Sampietro Colom, Joice Valentim, Rosa Hidalgo Vivianco, Magdalena Ruth Moshi, Marco Marchetti
Summary: A hallmark digital health solution (DHS) is their quick development and continuous lifecycle. The cadence of traditional research approaches impedes the proper and timely DHS assessment. The panel will comprise of HTA professionals that will present new evidence generation approaches, discuss the challenge of balancing speed rigor of DHS assessments, and address the value DHS assessment adoption by HTA organizations.
Date, Time & Location: Monday, June 26 | 17:25PM - 18:40PM | Riverbank 4
Panelists: Americo Cicchetti, Alicia Granados, Andrea Rappagliosi, Dan Ollendorf, Manuel Antonio Espinoza, Francesco S. Mennini, Ann Single, Guy Maddern
Summary: The panel is designed to promote a genuine discussion among stakeholders involved in policy fora launched by HTAi at global and regional level and at a national level in Italy by the Italian Society of HTA. Which is the underlying value of this initiatives? What lessons have we learned in different contexts? How to foster collaboration?
Date, Time & Location: Monday, June 26 | 17:25PM - 18:40PM | Riverbank 7
Panelists: Nicole Mittmann, Karen Facey, Wim Goettsch, Sylvie Bouchard, Ashley Jaksa, Julie Cini
Summary: An international, multistakeholder panel will discuss opportunities and challenges related to HTA organizations collaborating on use of registry data to inform decision-making. Information needs to support decision-making about optimal care of paediatric spinal muscular atrophy will used as a case study.
Date, Time & Location: Monday, June 26 | 17:25PM - 18:40PM | Riverbank 8
Panelists: Martina Garau, Jonathan Karnon, Meindert Boysen, Wija Oortwijn, Suzanne McGurn
Summary: This panel will discuss the main drivers for change in Health Technology Assessment (HTA) methods and processes (M&P). Panelists from England, Australia, and The Netherlands will provide the policy-maker perspective on challenges and enablers of bringing HTA reforms in their jurisdictions; reflect on key learnings from HTA M&P's past reforms; and reflect on cross-border initiatives aimed at HTA harmonization.
Date, Time & Location: Monday, June 26 | 17:25PM - 18:40PM | Riverbank 3
Panelists: Colman Taylor, Andrea Kunca, Tiffany Boughtwood, Krystal Barter
Summary: Historically Health Technology Assessment (HTA) of genetic and genomic technologies has been challenging as the PICO is complex to define and evidence is often lacking. This session will provide an update on academic, industry and patient initiatives to improve HTA of genetic and genomic technologies as well as precision medicines that stem from the Australian HTA Summit.
Date, Time & Location: Monday, June 26 | 17:25PM - 18:40PM | Riverbank 6
Panelists: Phung Lam Toi, Jeonghoon Ahn, Johnathan Tan, Tracy Merlin, Rosalie Viney
Summary: Determining drug subsidization on the basis of cost-effectiveness is traditionally done by assessing the incremental cost-effectiveness ratio (ICER) versus a threshold. If the ICER is below the threshold the drug can be accepted for subsidization by the decision maker. This issue panel will discuss the issues related to using and setting an ICER threshold.
Date, Time & Location: Monday, June 26 | 17:25PM - 18:40PM | Hall C
Panelists: Anke Peggy Holtorf, Valentina Strammiello, Aline Silveira Silva, Eunice Low
Summary: An initiative by HTAi, EPF and EUPATI analyzed and used stakeholder experiences with current processes for patient involvement (PI) in European HTA to co-create recommendations on valued PI-processes. The implementation of the cocreated, evidence-informed recommendations and the role in fostering the quality, effectiveness and sustainability of participatory processes in HTA will be discussed with key stakeholders.
Date, Time & Location: Monday, June 26 | 17:25PM - 18:40PM | E 3
Panelists: Edward Cavanough, Morris Iemma, Penny George, Michelle Burke, Mark Neeham
Summary: Leaning on research by McKell institute and AstraZeneca, this panel discusses the economic outcomes of public investment in novel medicines. We will explore how the cost vs investment equation in listing decisions could contribute positively to Australia's economy while improving future population health management. We will discuss preparation needed by federal and state governments to effectively realise such contributions.
Date, Time & Location: Monday, June 26 | 17:25PM - 18:40PM | E 1
Panelists: Rosmin Esmail, Nora Ibargoyen-Roteta, Alric Ruether, Maxmilian Otte, Izzuna Mudla Mohamed Ghazali, Hans-Peter Dauben
Summary: The heads of the HTAi IG Disinvestment and Early Awareness (DEA) will present the curriculum on Early Awareness and Disinvestment and the aims of the IG in future visions. Representatives from INAHTA, HTAi and i-HTS will add their ideas, needs and existing services to improve the ecosystem for the area of training and capacity building for the HTA community.
SESSION 3
11:10 - 12:25
Date, Time & Location: Tuesday, June 27 | 11:10AM - 12:25PM | E 3
Panelists: Erni Zurina Romli, Charlotte Pelekanou, Suzanne McGurn, Jae Kyung Suh, Meindert Boysen, Wim Goettsch
Summary: This INAHTA panel will share experiences and current research about the benefits of aligning regulatory and reimbursement processes. Despite achievements in this area, a divergence in approach has created some deficiencies in evidence production for coverage decisions. The session presents INAHTA member agency experiences and the potential benefits and challenges of improved process alignment between public HTA bodies and regulators.
Date, Time & Location: Tuesday, June 27 | 11:10AM - 12:25PM | Riverbank 8
Panelists: Barry Liden, Dan Ollendorf, William Padula, Christoph Glaetzer
Summary: Arguably one of the single largest healthcare markets in the world, the United States is unique among developed countries in its lack of a coordinated or centralized approach to Health Technology Assessment. This panel brings experts with unique backgrounds and experience with the U.S. Healthcare System to discuss why and how to better address HTA needs in the U.S.
Date, Time & Location: Tuesday, June 27 | 11:10AM - 12:25PM | E 1
Panelists: Wija Oortwijn, Birol Tibet, Lyazzat Kosherbayeva, Nabil Seyidov, Rabia Sucu
Summary: The panelists will share HTA capacity-building efforts in their respective middle-income countries in Eastern Europe and Central Asia. Based on the fact that there is neither an “ideal model” nor a “one-size-fits-all model” that can meet the needs in capacity building, the panel will aim to offer an insight into which certain capacity-building efforts are needed or chosen in each setting.
Date, Time & Location: Tuesday, June 27 | 11:10AM - 12:25PM | Riverbank 5
Panelists: Nicole Mittmann, Paul Fennessy, Nick Meadows, Tara Schuller
Summary: HTA organizations share responsibility with other health system stakeholders to support sustainable health systems. This panel will explore perspectives on the inclusion of environmental considerations in HTA from a variety of perspectives including industry, HTA, health administration, and health systems. It will increase awareness, encourage discussion, and support the incorporation of environmental considerations into healthcare decision making.
Date, Time & Location: Tuesday, June 27 | 11:25AM - 12:40PM | Riverbank 4
Panelists: Americo Cicchetti, Marco Marchetti, Rossella Di Bidino, Iga Lipska, Laura Sampietro Colom, Guy Maddern, Andrey Avdeyev
Summary: HTA when applied in a hospital context responds to similar and different issues than national/regional HTA. Not uniform approaches are adopted to integrate the Hospital-Based HTA (HB-HTA) into the national frameworks. Therefore, which is the effective role and additional value of HB-HTA is still debated. The panel introduces to the different experiences of HBHTA to support the panel discussion.
Date, Time & Location: Tuesday, June 27 | 11:10AM - 12:25PM | Riverbank 7
Panelists: Jonathan Karnon, James Le Fevre, Penny Reeves, Pwee Keng Ho, Andrew Partington
Summary: This session focuses on the use of hospital-based HTA in relation to health service delivery models (not medical or pharmaceutical technologies). Speakers from Australia, New Zealand and Singapore will talk about their experiences and views on the (1) prioritisation of topics for hospital-based HTA, (2) methods for hospital-based HTA of delivery models and (3) decision making using completed HTAs.
Date, Time & Location: Tuesday, June 27 | 11:10AM - 12:25PM | Hall C
Panelists: Colman Taylor, Bonny Parkinson, Rachael Anderson, Clare Stuart
Summary: One aim of the Australian Health Technology Assessment (HTA) process is to identify uncertainty in the clinical, economic and financial evidence to inform context specific decision making. This session will provide an update on outputs from the Australian HTA Summit including the development of a joint stakeholder framework to manage uncertainty in HTA.
Date, Time & Location: Tuesday, June 27 | 11:10AM - 12:25PM | Riverbank 6
Panelists: Jani Mueller, Yingyao Chen, Izzuna Mudla Mohamed Ghazali, Andres Pichon-Riviere
Summary: The panelists will discuss the challenges and opportunities for establishing HTA organizations in low- and middle-income countries (LMICs). They will debate the necessity for a legal framework to ensure the sustainability of these organizations. The objective is to discuss the appropriate course of action for establishing such organizations by sharing insights and experiences.
SESSION 4
14:55 - 16:10
Date, Time & Location: Tuesday, June 27 | 14:55PM - 16:10PM | Gilbert Suite
Panelists: Manuel Espinoza, Pietro Refolo, Jane Thomas, Ramiro Gilardino, Camille Schubert, Ann Single
Summary: Despite Health Technology Assessment’s (HTA) intent to support policies for equitable health systems, health outcomes remain different across groups within countries. Health technology assessments rarely consider the distribution of outcomes across the population and their effects on equity. Can recent methodological developments that have brought new approaches to incorporate equity concerns into HTA improve funding decisions in healthcare?
Date, Time & Location: Tuesday, June 27 | 14:55PM - 16:10PM | E 3
Panelists: Wija Oortwijn, Iñaki Gutierrez Ibarluzea, Inka Heikkinen, Hans Peter Dauben
Summary: The panel will describe results of the HTAi-DIA working group on uncertainty on how to gain trust and confidence as well as a proposal of how to follow a pathway to increase common action on trustful data as need for future actions in healthcare and health service industry.
Date, Time & Location: Tuesday, June 27 | 14:55PM - 16:10PM | Riverbank 3
Panelists: Yingyao Chen, Lizheng Shi, Jeonghoon Ahn, Ruoyan Gai
Summary: It is a unique case to review HTA on the cellular and gene therapies and its policy in East Asia (e.g., China, Japan and South Korea) and United States, and it could summarize challenges for the disruptive technology and strengthen collaboration with capacity competency.
Date, Time & Location: Tuesday, June 27 | 14:55PM - 16:10PM | Riverbank 4
Panelists: Guy Maddern, Linda Mundy, Grace Huang, Izzuna Ghazali, Vanessa Xavier, Alex Best
Summary: Health technology assessment (HTA) is essential for priority-setting in health care; however, the capacity to conduct and use HTA in healthcare decision-making is often lacking.
Date, Time & Location: Tuesday, June 27 | 14:55PM - 16:10PM | Riverbank 8
Panelists: Katrina Lapham, Franz Pichler, Meindert Boysen, Tiffany Boughtwood, Klair Bayley, Paul Fennessey
Summary: Health Technology Assessment is modernizing in the face of rapid medical innovation, while health systems develop strategies to implement advanced therapeutics. New capabilities and more integrated approaches are emerging. However, do such reforms go far enough? Are broader system changes required? Using real world examples, this panel will discuss policy implications of disruptive innovation and potential ways forward.
Date, Time & Location: Tuesday, June 27 | 14:55PM - 16:10PM | E 1
Panelists: Karen Facey, Michel Tchan, Conan Donnelly, Pall Jonsson, Sheela Upadhyaya
Summary: Real-World Evidence (RWE) from Rare Disorders’ (RD) registries can explain the full clinical spectrum and natural history of RD. However, there are challenges associated with curating, analysing and interpreting registry data. This panel will discuss challenges and lessons learnt from 30 years of registries in RD and new ways to increase the value of data from RD registries for HTA.
Date, Time & Location: Tuesday, June 27 | 14:55PM - 16:10PM | Riverbank 7
Panelists: Siw Waffenschimidt, Justin Clark, Zachary Munn, Tara Schuller, Klas Moberg
Summary: One way to meet growing demand for HTA evidence within resource constraints is through collaboration and re-using and sharing evidence. The panel will discuss: “deciding on an evidence review type”, “collaborative work”, and “sharing/reusing/repurposing evidence“. The panel introduces the methods and provides best practice solutions from the perspective of HTA agencies and specialised systematic review teams.
Date, Time & Location: Tuesday, June 27 | 14:55PM - 16:10PM | Riverbank 5
Panelists: Jan Willem Versteeg, Wim Goettsch, Nicole Mittmann, Hong Ju, Andrew Bruce
Summary: The assessment of long-term (relative) effectiveness of new therapies in health technology assessment (HTA) is often surrounded by uncertainty due to limited follow-up in trials. How can HTA organizations deal with this uncertainty? This panel features new research on this topic and includes a discussion with stakeholders on the current state of HTA and possible tools for the future.
Date, Time & Location: Tuesday, June 27 | 14:55PM - 16:10PM | Hall C
Panelists: Americo Cichetti, Valentina Strammiello, Eugenio Di Brino, Rabia Sucu, Emma Andrews, Maria Teresa Petrangolini, Richard Vines
Summary: The empirical evidence gathered from the response to COVID-19, shows that we are confronted with volatility and uncertainty even in the context of Healthcare systems and none of them can fully operate without embedding civil society active participation. Citizen and patient associations increasingly contribute to the improvement of health services and to the development of sustainable and equitable health policies.
JUNE 28
SESSION 5
09:10 - 10:25
Date, Time & Location: Wednesday, June 28 | 09:10AM - 10:25AM | Riverbank 6
Panelists: Jung der Wang, Paul Dickman, Jing Shiang Hwang, Mathuros Tipayamongkholgul
Summary: In health technology assessment based on real world data, one would extrapolate the survival function to lifetime, which could be multiplied with quality of life and costs at each time point and summed up throughout life for cost-effectiveness analysis. Two methods are introduced: flexible parametric model (FPM) by Karolinska Institute and the rolling extrapolation algorithm (REA) by Taiwan team.
Date, Time & Location: Wednesday, June 28 | 09:10AM - 10:25AM | Riverbank 3
Panelists: Simon Fifer, Sarah Norris, Nicole Millis, Gillian Mason, Jack Nunn, Deborah Marshall
Summary: Genomic tests are becoming increasingly important in healthcare systems around the world. Defining, measuring and applying patient and community values of these tests is challenging for many HTA bodies. The panel will discuss issues around valuation and co-design a research pilot which measures patient / community preferences of value, including clinical and personal utility (e.g., value of knowing).
Date, Time & Location: Wednesday, June 28 | 09:10AM - 10:25AM | Riverbank 7
Panelists: Daniel Ollendorf, Meindert Boysen, Nicole Mittmann, Andrew Wilson, Ann Single, Gavin Lewis
Summary: Regulators are collaborating to introduce pathways to accelerate authorization of promising new medicines. Project Orbis is an example of such an initiative in oncology. Accelerated access pathways can present challenges to HTA agencies – and patient access – where authorization is granted on evidence that HTA considers immature. This panel will present the perspectives of major HTAs, patients, and industry.
Date, Time & Location: Wednesday, June 28 | 09:10AM - 10:25AM | E 1
Panelists: Colman Taylor, Lucas Tocchini, Sallie Pearson, Jessica Bean
Summary: Historically there has been a disconnect between academic, industry and patient stakeholders with respect to accessibility and use of RWE. This session will provide an update on academic, industry and patient initiatives to improve access to RWE that stem from the Australian HTA Summit.
Date, Time & Location: Wednesday, June 28 | 09:10AM - 10:25AM | E 3
Panelists: Marcelien Callenbach, Wim Goettsch, Camille Schubert
Summary: The desirability of outcome-based reimbursement and delayed payment models are frequently debated. This panel will discuss a calculation tool developed for Libmeldy to quantify the costs associated with different payment models to provide insight when which type of agreement is most suitable given the particularities of the health innovation in question and how this could support future reimbursement decision-making.
Date, Time & Location: Wednesday, June 28 | 09:10AM - 10:25AM | Hall C
Panelists: Jacqueline Parsons, François Houÿez, Rob Camp
Summary: A genuine workshop on an innovative method to improve the accuracy of Horizon Scanning in HTA: asking patients how they view different emerging technologies of interest for their disease, on which criteria they base their ranking.
Date, Time & Location: Wednesday, June 28 | 09:10AM - 10:25AM | Riverbank 4
Panelists: Manuel Espinoza, Andres Pichon-Riviere, Sebastian Garcia Marti, Joice Valentim
Summary: This interactive panel session will report back and build upon the discussions from the 2022 Latin America Policy Forum (LATAM PF). An introductory presentation will summarize the discussions and major outcomes of the LATAM PF meeting, and will be followed by reactions from HTA, industry, payer, and patient stakeholder representatives. Interaction with the audience will be enhanced by live polling.
Date, Time & Location: Wednesday, June 28 | 09:10AM - 10:25AM | Riverbank 5
Panelists: Yingyao Chen, Lizheng Shi, Lei Si, Yan Wei, Shimeng Liu
Summary: It is an important and interesting panel focusing on how to explore quantitative patient preferences using some common approaches, such as DCE or BWS, and the experiences of integrating patient preference evidence into HTA from the perspective of China, United States and some other countries.
HTAi 2023 ANNUAL MEETING
© Copyright 2023 HTAi